Abstract
Site directed drug delivery with high efficacy is the biggest challenge in the area of current pharmaceuticals. Biodegradable polymer-based controlled release nanoparticle platforms could be beneficial for targeted delivery of therapeutics and contrast agents for a myriad of important human diseases. Biodegradable nanoparticles, which can be engineered to load multiple drugs with varied physicochemical properties, contrast agents, and cellular or intracellular component targeting moieties, have emerged as potential alternatives for tracking and treating human diseases. In this review, we will highlight the current advances in the design and execution of such platforms for their potential application in the diagnosis and treatment of variety of diseases ranging from cancer to Alzheimer’s and we will provide a critical analysis of the associated challenges for their possible clinical translation.
Keywords: Active targeting, biomaterials, blood-brain barrier, cancer, cardiovascular diseases, liposome, neurodegenerative diseases, nanomedicine, nanotechnology, polymer, passive targeting.
Current Medicinal Chemistry
Title:Nanocarriers for Tracking and Treating Diseases
Volume: 20 Issue: 28
Author(s): Sean Marrache, Rakesh Kumar Pathak, Kasey L. Darley, Joshua H. Choi, Dhillon Zaver, Nagesh Kolishetti and Shanta Dhar
Affiliation:
Keywords: Active targeting, biomaterials, blood-brain barrier, cancer, cardiovascular diseases, liposome, neurodegenerative diseases, nanomedicine, nanotechnology, polymer, passive targeting.
Abstract: Site directed drug delivery with high efficacy is the biggest challenge in the area of current pharmaceuticals. Biodegradable polymer-based controlled release nanoparticle platforms could be beneficial for targeted delivery of therapeutics and contrast agents for a myriad of important human diseases. Biodegradable nanoparticles, which can be engineered to load multiple drugs with varied physicochemical properties, contrast agents, and cellular or intracellular component targeting moieties, have emerged as potential alternatives for tracking and treating human diseases. In this review, we will highlight the current advances in the design and execution of such platforms for their potential application in the diagnosis and treatment of variety of diseases ranging from cancer to Alzheimer’s and we will provide a critical analysis of the associated challenges for their possible clinical translation.
Export Options
About this article
Cite this article as:
Marrache Sean, Pathak Kumar Rakesh, Darley L. Kasey, Choi H. Joshua, Zaver Dhillon, Kolishetti Nagesh and Dhar Shanta, Nanocarriers for Tracking and Treating Diseases, Current Medicinal Chemistry 2013; 20(28) . https://dx.doi.org/10.2174/0929867311320280007
DOI https://dx.doi.org/10.2174/0929867311320280007 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Pharmacologic Approach to Heart Failure in Children
Current Cardiology Reviews Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Ventricular Arrhythmias in Patients with Obstructive Sleep Apnea
Current Cardiology Reviews Impact of Hyperhomocyst(e)inemia on Endothelial Function
Vascular Disease Prevention (Discontinued) Antioxidants in Peripheral Arterial Disease
Current Drug Targets CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Role of Curcumin in Modulating Plasma PON1 Arylesterase Activity and Susceptibility to LDL Oxidation in Oxidatively Challenged Wistar Rats
Letters in Drug Design & Discovery Sea, Carbohydrates and Clotting: A Triad on the Road of Drug Discovery
Mini-Reviews in Medicinal Chemistry Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Bayes Syndrome and Imaging Techniques
Current Cardiology Reviews Blood Coagulation and the Risk of Atherothrombosis
Current Genomics